Lung Cancer Prevention and Treatment: Absin Empowers the Development of Inhalable Nanovaccines

As a malignant tumor with both high global incidence and mortality rates, lung cancer has long been a key focus in the field of medical research. Recently, a study titled A Noninvasive and Highly Effective Inhaled Nanovaccine Based on Natural Polysaccharide for Lung Cancer Treatment, published in ADVANCED MATERIALS, has brought a new breakthrough to lung cancer prevention and treatment. The inhalable nanovaccine (DDP/LLC) based on natural polysaccharides has demonstrated excellent preventive effects, and Absin's ELISA kits played a crucial role in verifying the research results by providing reliable support.

The DDP/LLC nanovaccine developed by the research team can induce a strong local immune response in the lungs through nasal inhalation. In mouse models, it achieved a 50% six-month survival rate and a 33% survival rate after secondary tumor challenge. Its core mechanism lies in activating the maturation of dendritic cells (DCs), the proliferation of T cells, and the retention of memory T cells (Tₐₘ).

In the process of verifying the immune response induced by the vaccine, Absin's IFN-γ ELISA Kit (abs520007) and TNF-α ELISA Kit (abs520010) became key tools:

• Quantifying immune factor secretion: By detecting the concentrations of IFN-γ and TNF-α in the peripheral blood of mice, it was directly proven that the DDP/LLC vaccine can significantly increase the levels of pro-inflammatory cytokines. After the secondary tumor challenge, the IFN-γ content in the vaccine group was 2.3 times higher than that in the control group, and the TNF-α content was 1.8 times higher, confirming the existence of long-term immune memory.

• Supporting key conclusions: Data showed that the level of cytokines induced by the inhalable immunization strategy was significantly higher than that of the traditional subcutaneous injection, providing direct evidence for the conclusion that "mucosal immunity activates local responses more efficiently".

Why Choose Absin? Solid Support from Scientific-Grade Quality

1. High Sensitivity to Capture Subtle Changes

The immune response induced by vaccines is often accompanied by slight fluctuations in cytokines. Absin's kits have a detection limit as low as the pg level, which can accurately capture the differences between the DDP/LLC group and the control group. Even low-level secretion during the immune memory stage can be stably detected.

2. High Specificity to Eliminate Interference

The experiment involved a complex tumor microenvironment and the cross-action of multiple cytokines. Through the design of specific antibodies, Absin's kits effectively avoid non-specific binding, ensuring the authenticity and reliability of the detection results of IFN-γ and TNF-α.

3. Convenient Operation to Adapt to High-Throughput Needs

In the study, it was necessary to detect samples at multiple time points (e.g., 7 days after immunization, 1 week after secondary challenge) and in multiple groups. The homogeneous reaction system and standardized process of Absin's kits greatly improved the experimental efficiency and helped the research team quickly verify the long-term efficacy of the vaccine.

In addition to the IFN-γ and TNF-α detection kits, Absin also provides detection solutions covering various cytokines such as IL-6 and IL-1β, which are suitable for research in multiple fields including tumor immunity and inflammatory response, helping to advance your experiments efficiently.

References

A Noninvasive and Highly Effective Inhaled Nanovaccine Based on Natural Polysaccharide for Lung Cancer Treatment. Adv. Mater. 2025, e04987

Related products